Wealthfront Advisers LLC Has $22.31 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Wealthfront Advisers LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 46.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 365,783 shares of the biopharmaceutical company's stock after purchasing an additional 116,178 shares during the period. Wealthfront Advisers LLC's holdings in Bristol Myers Squibb were worth $22,309,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BMY. Brighton Jones LLC raised its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $13,094,000. Proficio Capital Partners LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $240,000. Madison Investment Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $213,000. Finally, Natixis Advisors LLC raised its position in shares of Bristol Myers Squibb by 52.5% during the 4th quarter. Natixis Advisors LLC now owns 680,841 shares of the biopharmaceutical company's stock valued at $38,508,000 after acquiring an additional 234,477 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Up 1.6%

NYSE BMY traded up $0.73 on Wednesday, reaching $47.16. The company had a trading volume of 13,248,827 shares, compared to its average volume of 12,808,645. The firm has a market capitalization of $95.98 billion, a price-to-earnings ratio of 17.66, a price-to-earnings-growth ratio of 2.39 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb Company has a 1-year low of $41.20 and a 1-year high of $63.33. The company's fifty day moving average is $47.42 and its 200-day moving average is $53.06.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($4.40) EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.26%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 92.88%.

Wall Street Analyst Weigh In

BMY has been the subject of several recent research reports. UBS Group dropped their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Finally, Morgan Stanley decreased their price target on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $57.69.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.